Edgewise Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
EWTX$46.53-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share data)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three months ended September 30, · · Nine months ended September 30, | ||||||||||||
| · · 2026 · · 2025 · · 2026 · · 2025 | ||||||||||||
| | | | | | | | | | | | | |
| Operating expenses · · · · · · · · · · | ||||||||||||
| Research and development | | $31,575 | | $37,480 | | $121,774 | | $107,795 | ||||
| General and administrative | | 14,568 | | 9,378 | | 40,427 | | 27,632 | ||||
| Total operating expenses | | 46,143 | | 46,858 | | 162,201 | | 135,427 | ||||
| | | | | | | | | | | | | |
| Loss from operations | | (46,143) | | (46,858) | | (162,201) | | (135,427) | ||||
| | | | | | | | | | | | | |
| Other income | | | | | | | | | ||||
| Interest income | | 16,496 | | 6,192 | | 26,214 | | 17,848 | ||||
| Other income | | 3,065 | | — | | 3,065 | | — | ||||
| Gain on the Sevasemten Sale | | | 1,348,066 | | | — | | | 1,348,066 | | | — |
| Total other income | | 1,367,627 | | 6,192 | | 1,377,345 | | 17,848 | ||||
| | | | | | | | | | | | | |
| Income (loss) before income tax expense | | | 1,321,484 | | | (40,666) | | | 1,215,144 | | | (117,579) |
| Income tax expense | | | 155,333 | | | — | | | 155,333 | | | — |
| Net income (loss) | | | 1,166,151 | | | (40,666) | | | 1,059,811 | | | (117,579) |
| | | | | | | | | | | | | |
| Other comprehensive income (loss): | | | | | | | | | | | | |
| Unrealized (loss) gain on available-for-sale securities, net | | | (5,102) | | | 497 | | | (6,279) | | | 281 |
| Total comprehensive income (loss) | | $1,161,049 | | $(40,169) | | $1,053,532 | | $(117,298) | ||||
| | | | | | | | | | | | | |
| Basic earnings (loss) per share | | $10.71 | | $(0.39) | | $9.82 | | $(1.15) | ||||
| Diluted earnings (loss) per share | | $9.65 | | $(0.39) | | $8.86 | | $(1.15) | ||||
| Weighted-average shares outstanding used in basic earnings (loss) per share | | 108,870,331 | | 105,492,779 | | 107,892,028 | | 101,892,400 | ||||
| Weighted-average shares outstanding used in diluted earnings (loss) per share | | | 120,874,085 | | | 105,492,779 | | | 119,643,866 | | | 101,892,400 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.